Fluvoxamine: Clinical Trials

22 trials of Fluvoxamine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

21 completed, 1 unknown. 22 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 122Completed 21, Unknown 1

Follow Fluvoxamine: new trials by email Literature Review of Fluvoxamine trials Research Report on Fluvoxamine

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers
KP-001, Rosuvastatin calcium10mg, Caffeine citrate - Healty Volunteers
Phase 1CompletedKaken Pharmaceutical382025-02-132025-09-12
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects
Fluvoxamine, Itraconazole, Paroxetine - Drug Drug Interaction
Phase 1CompletedAsceneuron S.A.502024-02-222024-12-18
A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects
Savolitinib, Fluvoxamine - Healthy Male Subjects
Phase 1CompletedAstraZeneca162023-06-022023-08-29
Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant
Miricorilant, Fluvoxamine - Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
Phase 1CompletedCorcept Therapeutics262023-01-242023-03-22
A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)
anle138b (TEV-56286), Fluvoxamine 100 mg QD for 5 days - Healthy Volunteers
Phase 1CompletedMODAG GmbH542022-09-122023-03-23
Risk of CYP2C19 Phenoconversion in Healthy Volunteers With Rapid, Normal, and Intermediate Predicted Metabolizers' Status
Voriconazole 200mg, FluvoxaMINE 50 Mg Oral Tablet, Omeprazole 10 MG Oral Tablet - Healthy
Phase 1UnknownUniversity Hospital, Geneva452022-04-012022-11-03
Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464
Caffeine, ABX464, Fluvoxamine - Healthy
Phase 1CompletedAbivax S.A.592020-12-172026-11-09
A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers
AZD4635, Fluvoxamine - Healthy Volunteer/DDI Study
Phase 1CompletedAstraZeneca282020-07-212021-01-06
Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165
BMS-986165, Fluvoxamine - Healthy
Phase 1CompletedBristol-Myers Squibb162019-05-012021-11-17
Drug-Drug Interaction (DDI) Study for TD-9855
TD-9855, Fluvoxamine, Itraconazole - Drug Drug Interaction (DDI)
Phase 1CompletedTheravance Biopharma412018-02-282021-01-14
Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122
CC-122, Itraconazole, Fluvoxamine - Healthy Volunteer
Phase 1CompletedCelgene812017-11-092019-01-16
Influence of Fluvoxamine on the Pharmacokinetics of BI 409306
Fluvoxamine, BI 409306 - Powder for oral solution (PfOS), BI 409306 - film coated tablet - Healthy
Phase 1CompletedBoehringer Ingelheim182016-08-252024-08-21
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.
dovitinib (TKI258), fluvoxamine - Advanced Solid Tumors, Excluding Breast Cancer
Phase 1CompletedNovartis Pharmaceuticals452013-05-012020-12-21
A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
Pomalidomide, Ketoconazole, Fluvoxamine - Pharmacology, Clinical, Healthy
Phase 1CompletedCelgene322012-09-012019-11-12
A Study of the Effect of Fluvoxamine on the Pharmacokinetics of RO4917523 in Healthy Volunteers
Fluvoxamine, RO4917523 - Healthy Volunteer
Phase 1CompletedHoffmann-La Roche162012-07-012016-11-02
Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine
Tasimelteon, Fluvoxamine - Healthy Volunteers
Phase 1CompletedVanda Pharmaceuticals242012-02-012014-02-17
Impact of Citalopharm and Fluvoxamine on Platelet Response to Clopidogrel
fluvoxamine, citalopharm - Drug Interactions Between Clopidogrel and Serotonin Reuptake Inhibitors
Phase 1CompletedHadassah Medical Organization152011-09-012013-01-29
Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers
FK949E, fluvoxamine - Healthy, Pharmacokinetics of Quetiapine
Phase 1CompletedAstellas Pharma Inc242011-07-012017-02-16
Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel
omeprazole, fluvoxamine, placebo - Drug Interaction of Clopidogrel
Phase 1CompletedHadassah Medical Organization152011-01-012015-08-19
Kinetics of Fluvoxamine and Digoxin in Subjects With Different MDR1 Genotypes
fluvoxamine, Digoxin - Depression
Phase 1CompletedKarolinska Institutet142008-08-012015-09-01

Showing 20 of 22. Sign in to see all of them.

Conditions studied

Alzheimer Disease (1)  ·  Depression (1)  ·  Multiple System Atrophy (1)  ·  Neurodegenerative Diseases (1)  ·  Non-alcoholic Fatty Liver Disease (1)  ·  Parkinson Disease (1)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (1)  ·  Smoking (1)  ·  Tauopathies (1)

Sponsors

AstraZeneca (2)  ·  Celgene (2)  ·  Hadassah Medical Organization (2)  ·  Abivax S.A. (1)  ·  Asceneuron S.A. (1)  ·  Astellas Pharma Inc (1)  ·  Avigen (1)  ·  Boehringer Ingelheim (1)  ·  Bristol-Myers Squibb (1)  ·  Corcept Therapeutics (1)  ·  Heidelberg University (1)  ·  Hoffmann-La Roche (1)  ·  Kaken Pharmaceutical (1)  ·  Karolinska Institutet (1)  ·  MODAG GmbH (1)

Countries

United States (10)  ·  United Kingdom (3)  ·  Germany (2)  ·  Netherlands (2)  ·  Switzerland (2)  ·  Denmark (1)  ·  France (1)  ·  Israel (1)  ·  Japan (1)  ·  Sweden (1)

Top investigators

Caroline Samer, Prof (1)  ·  Joseph Custodio, PhD (1)  ·  Leon Carayannopoulos, MD (1)  ·  Maria Palmisano, MD (1)  ·  Nand Singh, MD (1)  ·  Pablo Forte Soto, Dr. (1)  ·  Paul Gineste (1)  ·  Rolf Pokorny, MD (1)

Results publications

PMID 25689244, PMID 29101463

NIH funding

2016 (1)